NCT06177028View on ClinicalTrials.gov

MCLENA-2: A Phase II Clinical Trial for the Assessment of Lenalidomide in Patients With Mild Cognitive Impairment

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

January 2, 2026

Study Completion Date

January 2, 2027

Conditions
Cognitive Impairment, MildCognitive DysfunctionAmyloid PlaqueNeurodegenerative Disease, HereditaryInflammation, Brain
Interventions
DRUG

Lenalidomide 10 mg

Lenalidomide is a cancer drug, It is also known by it's brand name Revlimid.

All Listed Sponsors
collaborator

Texas Tech University

OTHER

lead

St. Joseph's Hospital and Medical Center, Phoenix

OTHER